DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025 Fireside chat at 6:55 a.m. PDT / 9:55 a.m.
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection poi...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Offic...
– Total revenues of $898 million in 1Q25 –– Xywav ® and Epidiolex ® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 –– Completed submission of sNDA for Zepzelca ® in 1L ES-SCLC –– Affirming 2025 revenue guidance; updating financial guidance to reflect Chimerix acquisition and impact of certain Xyrem® antitrust litigation settlements – DUBLIN , May 6, 2025 /PRNewswire/ -- Jazz Pha...
DUBLIN , April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m.
DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibod...
Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients Long-term outcomes and survival data for Ziihera ® (zanidatamab-hrii) ...
DUBLIN , April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.